Categories
Change Password!
Reset Password!
To determine the i). Efficacy of triple therapy based on levofloxacin-dexlansoprazole as a usual therapy for H. pylori infection and ii). Assess the effect of H. pylori on lipid panel and hemoglobin (Hb).
Levofloxacin-based triple therapies are regarded as the
typical therapy for Helicobacter pylori (H. pylori) eradication due to reduced
sensitivity to clarithromycin. This pilot
prospective randomized study proved that levofloxacin-dexlansoprazole
based therapy had maximum eradication rate for this bacterial infection when
used for 10 days.
This study comprised of 66 patients with H. pylori infection
on triple therapy [(Levofloxacin 500 mg/day, Amoxicillin 1 g/12 hours,
Dexlansoprazole 60 mg/day, LAD] administrated orally for either 7 or 10 days.
The stool antigen test was used to assess eradictation 4 weeks following the
therapy.
Eradication rate was 63.6% in patients on LAD therapy for 7
days as compared to 90.9% when used for 10 days. Considerable difference in
low-density and high-density lipoprotein, triglyceride, Hb and total
cholesterol levels prior to and following the therapy was observed.
The use of LAD treatment for a period of 10 days is the
least time that offers maximum efficacy for H. Pylori infection. Additionally,
efficacious therapy of H. pylori infection may lessen anemia and dyslipidemia
risk. All the members of the patient's family should be examined for H. pylori
to decrease the chances of repeated infection.
Indian Journal of Pharmacology
Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of Helicobacter pylori: A pilot randomized trial
Noha Mahmoud Elkhodary et al.
Comments (0)